Login to Your Account



Biotica Signs MTOR Inhibitor Deal With Wyeth For $195M

By Jennifer Boggs


Friday, October 6, 2006
Biotica Technology Ltd. partnered a preclinical program targeting mTOR (mammalian target of rapamycin) in a potential $195 million deal with Wyeth Pharmaceuticals to develop compounds against multiple indications, including inflammatory diseases and cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription